{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T13:49:39Z","timestamp":1762004979798,"version":"build-2065373602"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2017,9,20]],"date-time":"2017-09-20T00:00:00Z","timestamp":1505865600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","award":["H26-28"],"award-info":[{"award-number":["H26-28"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare","doi-asserted-by":"publisher","award":["H26-H28"],"award-info":[{"award-number":["H26-H28"]}],"id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism Reports"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1016\/j.ymgmr.2017.12.004","type":"journal-article","created":{"date-parts":[[2017,12,21]],"date-time":"2017-12-21T23:30:31Z","timestamp":1513899031000},"page":"68-72","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Ten-year-long enzyme replacement therapy shows a poor effect in alleviating giant leg ulcers in a male with Fabry disease"],"prefix":"10.1016","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9895-0762","authenticated-orcid":false,"given":"Jun","family":"Okada","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad Arif","family":"Hossain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0752-3088","authenticated-orcid":false,"given":"Chen","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Miyajima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroko","family":"Yanagisawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiko","family":"Akiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshikatsu","family":"Eto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgmr.2017.12.004_bb0005","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1056\/NEJM196705252762101","article-title":"Enzymatic defect in Fabry's disease: ceramide trihexosidase deficiency","volume":"276","author":"Brady","year":"1967","journal-title":"N. Eng. J. Med."},{"key":"10.1016\/j.ymgmr.2017.12.004_bb0010","series-title":"The Metabolic and Molecular Bases of Inherited Disease","first-page":"3733","article-title":"a-Galactosidase a deficiency: fabry disease","author":"Desnick","year":"2001"},{"key":"10.1016\/j.ymgmr.2017.12.004_bb0015","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1001\/archneur.63.3.453","article-title":"Later-onset Fabry disease: an adult variant presenting with the cramp-fasciculation syndrome","volume":"63","author":"Nance","year":"2006","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.ymgmr.2017.12.004_bb0020","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1136\/jmedgenet-2014-102872","article-title":"Plasma globotriaosylsphingosine in relation to phenotypes of Fabry disease","volume":"52","author":"Smid","year":"2015","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.ymgmr.2017.12.004_bb0025","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.jpeds.2007.09.007","article-title":"Safety and efficacy of enzyme replacement therapy with agalsidase beta: an international, open-label study in pediatric patients with Fabry disease","volume":"152","author":"Wraith","year":"2008","journal-title":"J. Pediatr."},{"key":"10.1016\/j.ymgmr.2017.12.004_bb0030","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1136\/jmedgenet-2014-102797","article-title":"Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry disease","volume":"52","author":"Germain","year":"2015","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.ymgmr.2017.12.004_bb0035","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1159\/000448968","article-title":"Long term treatment with enzyme replacement therapy in patients with Fabry disease","volume":"134","author":"Oder","year":"2016","journal-title":"Nephron"},{"key":"10.1016\/j.ymgmr.2017.12.004_bb0040","article-title":"Lucerastat, an iminosugar for substrate reduction therapy: tolerability, pharmacodynamics, and pharmacokinetics in patients with Fabry disease on enzyme replacement","author":"Gu\u00e9rard","year":"2017","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ymgmr.2017.12.004_bb0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejmech.2016.10.004","article-title":"Rapid preparation of (3R,4S,5R) polyhydroxylated pyrrolidine-based libraries to discover a pharmacological chaperone for treatment of Fabry disease","volume":"126","author":"Cheng","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ymgmr.2017.12.004_bb0050","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.omtm.2017.05.003","article-title":"Lentivector iterations and pre-clinical scale-up\/toxicity testing: targeting mobilized CD34+ cells for correction of Fabry disease","volume":"5","author":"Huang","year":"2017","journal-title":"Mol. Ther. Meth. Clin. Dev."},{"key":"10.1016\/j.ymgmr.2017.12.004_bb0055","first-page":"363","article-title":"Multiple leg ulcers in a patient with Fabry disease","volume":"22","author":"Nakai","year":"2007","journal-title":"JEADV"},{"key":"10.1016\/j.ymgmr.2017.12.004_bb0060","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.gene.2013.11.003","article-title":"Late-onset Krabbe disease is predominant in Japan and its mutant precursor protein undergoes more effective processing than the infantile-onset form","volume":"534","author":"Hossain","year":"2014","journal-title":"Gene"},{"key":"10.1016\/j.ymgmr.2017.12.004_bb0065","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.ymgme.2017.01.002","article-title":"The severe clinical phenotype for a heterozygous Fabry female patient correlates to the methylation of non-mutated allele associated with chromosome 10q26 deletion syndrome","volume":"120","author":"Hossain","year":"2017","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgmr.2017.12.004_bb0070","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1111\/j.1523-1755.2004.00924.x","article-title":"Enzyme therapy for Fabry disease: neutralizing antibodies toward agalsidase alpha and beta","volume":"66","author":"Linthorst","year":"2004","journal-title":"Kidney Int."},{"issue":"Suppl. 3","key":"10.1016\/j.ymgmr.2017.12.004_bb0075","doi-asserted-by":"crossref","first-page":"S249","DOI":"10.1007\/s10545-010-9136-0","article-title":"Enzyme replacement therapy in a patient with Fabry disease and the development of IgE antibodies against agalsidase beta but not agalsidase alpha","volume":"33","author":"Tanaka","year":"2010","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgmr.2017.12.004_bb0080","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1007\/s10038-005-0342-9","article-title":"Comparison of the effects of agalsidase alfa and agalsidase beta on cultured human Fabry fibroblasts and Fabry mice, J","volume":"51","author":"Sakuraba","year":"2006","journal-title":"Hum. Genet."},{"key":"10.1016\/j.ymgmr.2017.12.004_bb0085","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.ymgme.2008.10.004","article-title":"A retrospective analysis of the potential impact of IgG antibodies to agalsidase beta on efficacy during enzyme replacement therapy for Fabry disease","volume":"96","author":"Benichou","year":"2009","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgmr.2017.12.004_bb0090","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ymgme.2015.11.001","article-title":"Immune response to enzyme replacement therapies in lysosomal storage diseases and the role of immune tolerance induction","volume":"117","author":"Kishnani","year":"2016","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgmr.2017.12.004_bb0095","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1086\/318809","article-title":"A phase 1\/2 clinical trial of enzyme replacement in fabry disease: pharmacokinetic, substrateclearance, and safety studies","volume":"68","author":"Eng","year":"2001","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.ymgmr.2017.12.004_bb0100","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/joim.12647","article-title":"Impact of immunosuppressive therapy on therapy-neutralizing antibodies in transplanted patients with Fabry disease","volume":"282","author":"Lenders","year":"2017","journal-title":"J. Intern. Med."}],"container-title":["Molecular Genetics and Metabolism Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214426917301349?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214426917301349?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T12:49:33Z","timestamp":1762001373000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2214426917301349"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":20,"alternative-id":["S2214426917301349"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgmr.2017.12.004","relation":{},"ISSN":["2214-4269"],"issn-type":[{"type":"print","value":"2214-4269"}],"subject":[],"published":{"date-parts":[[2018,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ten-year-long enzyme replacement therapy shows a poor effect in alleviating giant leg ulcers in a male with Fabry disease","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgmr.2017.12.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}